Results 41 to 50 of about 482,975 (382)

Anticoagulants for acute ischaemic stroke [PDF]

, 2015
Peer reviewedPublisher ...
Counsell, Carl, Kane, Edward J, Sandercock, Peter A G   +2 more
core   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M, Athanasoulis CA, Bergqvist D, Bergqvist D, Buller HR, Clagett PG, Da Silva MS, Decousus H, ENOXACAN Study Group, Falanga A, Geerts WH, Gitter MJ, Goldenberg N, Gomes MPV, Green D, Haas S, Heit JA, Hettiarachchi RJK, Hull R, Hutten BA, International Multicentre Trial, Johnson MJ, Kakkar VV, Karthaus M, Koopman MMW, Levine MN, Mousa S A, Mousa SA, Prandoni P, Rasmussen MS, Rickles FR, Sallah S, Samama M, Siragusa B, The Columbus Investigators, White RH, Zacharski LR   +36 more
core   +1 more source

The Anticoagulant and Nonanticoagulant Properties of Heparin

Thrombosis and Haemostasis, 2020
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, routine clinical anticoagulant use of heparin was initiated only after the publication of several seminal papers in the early 1970s by the group of Kakkar ...
D. Beurskens, Joram P. Huckriede, R. Schrijver, H. Hemker, C. Reutelingsperger, G. Nicolaes   +5 more
semanticscholar   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Trends in anticoagulant prescribing: a review of local policies in English primary care

BMC Health Services Research, 2020
Background Oral anticoagulants are prescribed for stroke prophylaxis in patients with atrial fibrillation, which is the most common heart arrhythmia worldwide. The vitamin K antagonist (VKA) warfarin is a long-established anticoagulant.
Katherine H. Ho, M. van Hove, G. Leng
semanticscholar   +1 more source

Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration

Journal of Thrombosis and Haemostasis, 2020
Coronavirus disease (COVID‐19) is associated with a high incidence of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise regarding the optimal dose of anticoagulant intervention in hospitalized patients with ...
T. Tritschler, M. Mathieu, L. Skeith, M. Rodger, S. Middeldorp, T. Brighton, P. Sandset, S. Kahn, D. Angus, M. Blondon, M. Bonten, M. Cattaneo, M. Cushman, L. Derde, M. Desancho, J. Diehl, E. Goligher, B. Jilma, P. Jüni, P. Lawler, M. Marietta, J. Marshall, C. McArthur, C. H. Miranda, T. Mirault, N. Morici, Usha Perepu, C. Schörgenhofer, M. Sholzberg, A. Spyropoulos, S. Webb, R. Zarychanski, S. Zuily, G. Le Gal   +33 more
semanticscholar   +1 more source

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

British medical journal, 2019
Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years ...
F. Khan, Alvi Rahman, M. Carrier, C. Kearon, J. Weitz, S. Schulman, F. Couturaud, S. Eichinger, P. Kyrle, C. Becattini, G. Agnelli, T. Brighton, A. Lensing, M. Prins, E. Sabri, B. Hutton, L. Pinède, M. Cushman, G. Palareti, G. Wells, P. Prandoni, H. Büller, M. Rodger   +22 more
semanticscholar   +1 more source

Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis, 2020
The laboratory detection of lupus anticoagulants (LA) in anticoagulated patients represents a challenge and there is no consensus on the types of assays/procedures to be adopted.
A. Tripodi, H. Cohen, K. Devreese
semanticscholar   +1 more source

High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia

Clinical Rheumatology, 2020
About 15–20% of patients with severe acute respiratory syndrome–coronavirus 2 (SARS-CoV2) disease experience pneumonia of variable extent and course [1]. A proportion of them have cardiovascular involvement, including myocarditis, ischemia and shock, and
C. Gazzaruso, Nicoletta Carlo Stella, G. Mariani, Carlo Nai, A. Coppola, Daniela Naldani, P. Gallotti   +6 more
semanticscholar   +1 more source

Medial Collateral Ligament Knee Injury in a Patient Receiving Rivaroxaban: A Cause of Acute Hemarthrosis [PDF]

Reviews in Clinical Medicine, 2020
Medial collateral ligament (MCL) injury is highly common in athletes and the elderly. This ligament is in the knee region and is often at the risk of injury.
Seyed Reza Habibzadeh, Mahdi Foroughian, Esmaeil Rayat Dost   +2 more
doaj   +1 more source